Alzheimer's disease drug development and the problem of the blood-brain barrier.
about
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseasesReal-time, transcranial monitoring of safe blood-brain barrier opening in non-human primates.Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's DiseaseA safe, blood-brain barrier permeable triphenylmethane dye inhibits amyloid-β neurotoxicity by generating nontoxic aggregatesDivergent synthesis of biflavonoids yields novel inhibitors of the aggregation of amyloid β (1-42).Brain Delivery of Drug and MRI Contrast Agent: Detection and Quantitative Determination of Brain Deposition of CPT-Glu Using LC-MS/MS and Gd-DTPA Using Magnetic Resonance Imaging.Biopharmaceutical drug targeting to the brain.Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles.Anti-dementia Activity of Nobiletin, a Citrus Flavonoid: A Review of Animal Studies.Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?Mesoporous silica nanoparticle-based H2O2 responsive controlled-release system used for Alzheimer's disease treatment.Cytotoxicity and apoptotic gene expression in an in vitro model of the blood-brain barrier following exposure to poly(butylcyanoacrylate) nanoparticles.Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brainCharacterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis.Driving drug discovery: the fundamental role of academic labs.The polysaccharide extracts from the fungi Coprinus comatus and Coprinellus truncorum do exhibit AChE inhibitory activity.Hematite-Based Photoelectrode Materials for Photoelectrocatalytic Inhibition of Alzheimer's β-Amyloid Self-Assembly.A 3D Real-Scale, Biomimetic, and Biohybrid Model of the Blood-Brain Barrier Fabricated through Two-Photon Lithography.Complement in the pathogenesis of Alzheimer's disease.Aerosol Delivery of Curcumin Reduced Amyloid-β Deposition and Improved Cognitive Performance in a Transgenic Model of Alzheimer's Disease.Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load.Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.Brain Targeting of 1,9-Pyrazoloanthrone an c-Jun-N-terminal Kinase Inhibitor Using Liposomes for Effective Management of Parkinson's Disease.Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer's disease.Sequential Virtual Screening Approach to the Identification of Small Organic Molecules as Potential BACE-1 Inhibitors
P2860
Q27026884-6A8F3E8B-A2DB-4AEB-A65D-4374C05C656BQ28539506-625F5F3B-62E1-403E-9500-21691106CCEBQ30376474-3EC4824D-26ED-4A49-B607-26CC208E96D7Q30423892-3E72D931-7AAD-495C-9B50-B3A26BC38B43Q36373920-80DFA45A-0BA3-4DA7-A424-2E79C4E13FAFQ37072186-A484EADC-56CA-4C78-9109-226ED6ACEC26Q37671828-BFE913F2-F676-4A69-ABEF-9E89CE5F8406Q38095485-E0E727B8-CC47-4242-98E2-FE2D3BB82667Q38246285-06C7C521-E453-439F-93ED-5F01BC03C0B6Q38592069-180E24D4-B82D-4181-9215-F94FD8444D73Q38675216-F70E25AE-1A4A-4618-AD76-08A3CB5B5F37Q39513747-56BCCB1B-4088-496C-B4D9-EBD067E746E7Q40167936-24354E9C-0153-4E31-BBBE-9287BE843894Q42591155-A214E616-8AE7-44F5-B766-93E6FD38B710Q44355626-0F96E3EE-3515-4630-8AF4-D16D265D812FQ45946985-66F9F065-103C-4958-9509-C02D0981F716Q46255915-3D7E9799-ECB2-4EA7-A019-D723A3818C4CQ46418238-1F72ACAA-68AE-465A-885E-40D61D5594E4Q47250972-D21EC2FA-4B31-4083-9EA1-E5062DB24441Q47709505-B79494BA-74D0-43F2-A1EC-ED7CD19D1675Q48447497-08869904-4866-4630-B513-7E6FBE923298Q48636523-4F4151BA-6060-4D20-8F23-E722C781F5F2Q48748554-6CED93B7-D725-4CF0-BFFA-9FE7B5B27B2FQ48829255-72741EAF-7BE1-4C5F-8B16-B9AF01CFA22FQ51733153-CC87776A-E48B-4161-A8DC-E2AC87ABFB82Q53349909-FD2E9019-2B1A-46A8-B0A5-E8F9ACB8180DQ57278508-3DD0886C-2C3F-4BB2-B1AA-9FD01C081AC7
P2860
Alzheimer's disease drug development and the problem of the blood-brain barrier.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alzheimer's disease drug development and the problem of the blood-brain barrier.
@en
Alzheimer's disease drug development and the problem of the blood-brain barrier.
@nl
type
label
Alzheimer's disease drug development and the problem of the blood-brain barrier.
@en
Alzheimer's disease drug development and the problem of the blood-brain barrier.
@nl
prefLabel
Alzheimer's disease drug development and the problem of the blood-brain barrier.
@en
Alzheimer's disease drug development and the problem of the blood-brain barrier.
@nl
P2860
P1476
Alzheimer's disease drug development and the problem of the blood-brain barrier.
@en
P2860
P304
P356
10.1016/J.JALZ.2009.06.003
P577
2009-09-01T00:00:00Z